<DOC>
	<DOCNO>NCT00568308</DOCNO>
	<brief_summary>The purpose study determine PI-88 effective safe patient surgery remove primary liver cancer .</brief_summary>
	<brief_title>Phase III Study PI-88 Post-resection Hepatocellular Carcinoma</brief_title>
	<detailed_description>Primary liver cancer ( hepatocellular carcinoma HCC ) fifth common cancer worldwide . Surgery remove tumour remain principal form treatment liver cancer , however recurrence disease surgery common survival recurrence poor . At moment recommend standard treatment HCC immediately tumour remove surgically . PI-88 new experimental drug block growth new blood vessel tumours stop tumour grow ( starves food ) also stop tumour cell spread . Previous experience PI-88 show well tolerate show benefit delaying time take hepatocellular carcinoma reappear surgery . The purpose study determine PI-88 effective safe patient surgery remove primary liver cancer .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>Key Histologicallyproven primary hepatocellular carcinoma curative resection perform 4 6 week prior randomisation . ECOG performance status 0 2 Child Pugh classification A B Key Any evidence tumour metastasis coexist malignant disease Any prior recurrence HCC liver resection prior recent procedure History prior HCC therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>PI-88</keyword>
	<keyword>Phase III</keyword>
	<keyword>Adjuvant Therapy</keyword>
	<keyword>Hepatoma</keyword>
	<keyword>Liver Cancer</keyword>
</DOC>